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 Inflammation plays a role at all stages of cancer. Inflammasomes are an 
integral part of inflammation response. Inflammasomes are large multiprotein 
complexes that are a part of innate immune system. They are potent inducers of 
maturation and secretion of pro-inflammatory interleukin (IL)-1β and IL-18 during 
inflammation [1]. Activation of inflammasomes causes a pro-inflammatory form of 
programmed cell death called pyroptosis accompanied by cytokine secretion [2]. 
Inflammasome is an important first line of immune defense, and its components tend 
to be expressed in epithelial tissues, where they respond to signals called danger-
associated molecular patterns (DAMPs) produced by the host cell [3].  
Proteins that are components of inflammasomes include pyrin, IFI16 (IFN-
inducible protein 16), AIM2 (absent in melanoma 2), and NLRs (nucleotide-binding 
oligomerization domain and leucine-rich repeat-containing receptors) [1]. Through 
the pyrin domain, the inflammasome interacts with the adaptor protein ASC which 
activates a caspase. In turn, caspase cleaves precursors of (IL)-1β and IL-18 which 
may activate the pyroptosis mode of the cell death. Cancer is often accompanied by 
dysregulation of inflammasome activation [4].  
We studied effect of differential gene expression in the inflammasome pathway 
[5]. on survival of patients with kidney renal clear cell carcinoma. We performed the 
Kaplan-Meier survival analysis using an online Kaplan-Meier plotter at 
https://kmplot.com/ that is capable to assess the effect of 54k genes on survival in 21 
Актуальні питання медичних наук:  
теоретичні та прикладні дослідження 
Медичні науки в цілому www.openscilab.org 
© Tsuber V.Y. 
112 
cancer types. The tool is used for discovery and validation of gene biomarkers of 
survival in cancer based on meta-analysis of massive cancer databases [6]. Sources 
for the databases include GEO, EGA, and TCGA. We performed the analysis of 530 
patients with kidney renal clear cell carcinoma for whom clinical data was available 
for analysis in the databases.  
We found a significant dysregulation of the inflammasome pathway, in which 
high expression of a number of genes of the pathway promotes survival of the 
patients, while high expression of another set of the inflammasome pathway genes 
decreases survival (Table 1).  
Table 1 





















High expression of these genes significantly increases survival 
APP 3.2e-9 0.0000007 0.41 0.30 – 0.55 1 23.6 56.5 
BCL2 1.5e-8 0.000003 0.43 0.32 – 0.58 1 22.6 54.2 
HSP90AB1 6.9e-5 0.01445 0.54 0.39 – 0.73 2 29.3 47.7 
NFKB1 2.9e-8 0.000006 0.44 0.55 – 0.59 1 24.2 54.2 
SUGT1 3.7e-6 0.00078 0.50 0.37 – 0.67 1 57.5 120.5 
High expression of these genes significantly decreases survival 
AIM2 2.2e-5 0.00462 1.92 1.41 – 2.60 1 54.2 29.4 
NFKB2 1.1e-6 0.00023 2.09 1.54 – 2.84 1 52.2 23.4 
PSTPIP1 9.8e-5 0.02058 2.15 1.45 – 3.19 3 71.5 31.8 
PYCARD 4.1e-8 0.000009 2.66 1.85 – 3.82 1 71.5 27.3 
High or low expression of these genes does not have significant effect on survival 
BCL2L1 0.0512  0.72 0.51 – 1.00 100 74.7 120.5 
CASP1 0.0379  1.40 1.02 – 1.92 over 50 118.5 74.2 
HMOX1 0.0015  0.62 0.46 – 0.83 50 70.2 120.5 
MEFV 0.0158  1.44 1.07 – 1.95 over 50 118.5 70.2 
NLRC4 0.1903  0.81 0.58 – 1.11 100 80.6 94.3 
NLRP1 0.0006  1.74 1.26 – 2.41 20 120.5 57.1 
NLRP3 0.0905  0.76 0.55 – 1.05 100 74.7 120.5 
P2RX7 0.2512  0.83 0.60 – 1.14 100 81.8 118.5 
PANX1 0.0009  1.69 1.24 – 2.31 20 118.5 63.7 
RELA 0.0883  1.31 0.96 – 1.80 100 118.5 74.7 
TXN 0.1028  1.29 0.95 – 1.76 100 45.7 33.4 
TXNIP 0.0001  0.46 0.31 – 0.69 3 33.1 74.7 
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 APP, BCL2, HSP90AB1, NFKB1, and SUGT1 are the genes that increase 
survival of the patients with when highly expressed. BCL2 is a regulator of apoptosis 
with a complex action [7]. In the case of kidney renal clear cell carcinoma, its high 
expression increases survival (Fig. 1). 
 
Figure 1. Effect of BCL2 on survival of patients with kidney renal clear cell carcinoma. 
 
NFKB1 is nuclear factor kappa B subunit 1 which in some cases drives cancer 
progression and in some cases acts as tumor suppressor [8]. We found, that its high 
expression significantly increases survival in kidney renal clear cell carcinoma (Fig. 
2). Interestingly, high expression of nuclear factor kappa B subunit 2 decreases 
survival in the cancer type.  
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Figure 2. Effect of NFKB1 on survival of patients with kidney renal clear cell carcinoma. 
AIM2, NFKB2, PSTPIP1, PYCARD are the genes that decrease survival of the 
patients with when highly expressed. PYCARD is apoptosis-associated speck-like 
protein containing a CARD (caspase activation and recruitment domain). It is a 
central adaptor molecule of the inflammasome complex, which mediates the secretion 
of inflammatory cytokines (i.e., IL-1β and IL-18) and has been reported to have dual 
role in carcinogenesis [9]. We found, that its high expression significantly decreases 
survival in kidney renal clear cell carcinoma (Fig. 3). 
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Figure 3. Effect of PYCARD on survival of patients with kidney renal clear cell carcinoma. 
In summary, we found that expression of the inflammasome pathway genes is 
highly dysregulated in kidney renal clear cell carcinoma. In addition, the effects of 
the genes that show the strongest influence on survival of patients with the disease 
differ from those that have been reported for some other cancer types. 
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